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Recentresearchhasrevealedrolesfortheperoxisomeproliferatoractivatedreceptor(PPAR)familyoftranscriptionfactorsinblood
pressure regulation, expanding the possible therapeutic use of PPAR ligands. PPARα and PPARγ modulate the renin-angiotensin-
aldosterone system (RAAS), a major regulator of systemic blood pressure and interstitial ﬂuid volume by transcriptional control
of renin, angiotensinogen, angiotensin converting enzyme (ACE) and angiotensin II receptor 1 (AT-R1). Blockade of RAAS is an
important therapeutic target in hypertension management and attenuates microvascular damage, glomerular inﬂammation and
left ventricular hypertrophy in hypertensive patients and also show antidiabetic eﬀects. The mechanisms underlying the beneﬁts of
RAASinhibition appear to involve PPARγ-regulated pathways. This review summarizes current knowledge on the role of PPARs in
the transcriptional control of the RAAS and the possible use of PPAR ligands in the treatment of RAAS dependent hypertension.
1.Introduction
Peroxisome proliferator activated receptors (PPARs), mem-
bers of the superfamily of ligand regulated transcription
factors, are expressed in the cardiovascular system and
control diverse vascular functions by mediating appropriate
c h a n g e st og e n ee x p r e s s i o n( r e v i e w e db y[ 1, 2]). PPARα,
PPARβ/δ and PPARγ isoforms are expressed in endothelial
cells, while vascular smooth muscle cells (VSMCs) express
only PPARα and PPARγ [1, 3]. PPARα and PPARβ/δ
aﬀectthevasculaturethroughseveralmechanisms, including
regulation of endothelial function, VSMC apoptosis, and
antiinﬂammatory properties via the control of cytokine
signaling and the downregulation of inﬂammatory cytokine
induced genes [1, 2, 4]. Moreover, PPAR gene mutations lead
to disturbances in blood pressure regulation. In humans,
both the Pro12Ala polymorphism and mutations in the
PPARγ gene contribute to hypertension [5, 6]. Mice lack-
ing PPARγ in VSMCs or endothelial cells show altered
arterial vasoconstriction [7], while PPARα knockout mice
develop salt-sensitive hypertension [8]. Fibrates, agonists of
PPARα, and thiazolidinediones (TZDs), ligands for PPARγ
have cholesterol- and triglyceride-lowering eﬀects and are
insulin sensitizers, with additional antiinﬂammatory and
antiatherogenic beneﬁts [9, 10] .T h e s ed r u g sa r ep r i m a r i l y
used in the treatment of lipid homeostasis disorders, type
2 diabetes mellitus and atherosclerosis [1, 2]. Hypertension
is a common comorbidity of atherosclerosis and insulin
resistance and clinical observations show that TZDs eﬀec-
tively reduce blood pressure in type 2 diabetic patients
[10–19]. TZDs also reduce peripheral resistance in several
experimental models of hypertension leading to reduced
bloodpressure[20].TheantihypertensiveeﬀectsofTZDsare
mediated by the vascular endothelia [20, 21] and through
an inhibitory action on VSMC L-type Ca2+-channels [9].
Endothelial function in hypertension is also improved by
ﬁbrates, and these compounds can reduce blood pressure in
patients with hypertriglyceridemia [22]. Recent studies indi-
catethatPPARγ-regulatedgeneexpressioncanalsoinﬂuence
the function of the renin-angiotensin-aldosterone system
(RAAS), thus allowing PPARγ ligands to alter vascular tone
and total body ﬂuid volume [13–15, 23]. An involvement
of PPARα in the modulation of the RAAS has also been
proposed, although its relevance to systemic blood pressure
regulation is still disputed [10, 19, 24].
The RAAS is a cascade formed by hormone-like sub-
stances released from the kidney and the adrenal gland, and
acts as a long-term regulator of systemic blood pressure2 PPAR Research
and interstitial ﬂuid volume (reviewed by [25]). The most
potent eﬀector molecule of the RAAS is angiotensin II
(Ang II), which elevates systemic blood pressure through
the constriction of blood vessels and furthermore enhances
aldosterone secretion, catecholamine release, sympathetic
nerve activity and myocardial contractility (Figure 1). Aldos-
terone, the other eﬀector molecule of the RAAS, contributes
to the maintenance of ﬂuid homeostasis and blood volume
through the regulation of the sodium and water resorbtion
capacity of the kidneys and the intestinal epithelium [25].
Aldosterone and Ang II can also act as paracrine factors,
and inﬂuence inﬂammation, mitogenesis, apoptosis and cell
growth, through which they contribute not only to the
development of hypertension but also to its cardiovascular
complications [16, 25–31], such as microvascular damage,
glomerular inﬂammation, podocyte injury and left ventric-
ular hypertrophy [32, 33]. A major medication strategy for
RAAS-dependent hypertension is therefore to block steps in
the RAAS cascade, thereby lowering systemic blood pressure
and reducing associated cardiovascular complications [25].
Newly identiﬁed roles of PPARγ and PPARα in the
modulation of blood pressure have already begun to expand
the potential therapeutic uses of PPARγ and PPARα ligands
[15, 21]. However, the role of PPARα in the regulation of
the RAAS is disputed [10], and unwanted hepatotoxic and
cardiac eﬀects of currently available PPARγ ligands [34, 35]
limit the use of these drugs in hypertension management. A
critical review of molecular mechanisms and physiological
consequences of PPAR activity in the RAAS is therefore
timely. In this review we summarize current knowledge
about the role of PPARγ and PPARα in the functioning of
the RAAS and discuss the possible modulation of RAAS-
dependent hypertension by these transcription factors at the
level of gene expression.
2. PPAR LigandsandMechanism of Action
The three diﬀerent PPAR subtypes (PPARα [NR1C1],
PPARβ/δ [NRC2] and PPARγ [NRC3]) have diﬀerent tissue
distribution and are involved in distinct biological processes.
PPARα is highly expressed in liver, heart, kidney cortex and
skeletal muscle; PPARβ/δ is abundantly expressed through-
out the body; and PPARγ is predominantly expressed in
adipose tissue, liver, kidney, skeletal muscle, monocytes and
macrophages [2]. PPARs, as ligand regulated transcription
factors, can modulate gene expression through binding to
hormone response elements in the promoter or enhancer
sequences of target genes [1, 2]. The domain strucure of
PPARs is similar to that of other nuclear receptors. A ligand-
independent transactivation amino-terminal domain is fol-
lowed by a DNA-binding domain (DBD) that contains zinc
ﬁnger motifs. The ligand binding domain (LBD) is located
at the carboxy terminus and is composed of several α helices
that form a hydrophobic ligand-binding pocket. The DBD
mediates PPAR binding to PPAR response elements (PPREs)
within the promoters of target genes. For DNA binding,
PPARs must dimerize with another nuclear receptor, the
retinoid X receptor (RXR). Heterodimers of PPARs and RXR
bind to PPREs and then activate expression of gene networks
involved in the controloflipid and carbohydratemetabolism
in several cell types. In addition, PPARs can also transrepress
proinﬂammatory genes by antagonizing the activities of
other transcription factors such as members of the nuclear
factor-κB( N F - κB) and activator protein-1 (AP-1) families.
Several lipid mediators and a variety of molecules that are
derived from fatty acid metabolism are natural ligands of
PPARs. In the last decade, much attention has focused on the
pharmacologicalmodulationofPPARs.Forexample,ﬁbrates
(cloﬁbrate, fenoﬁbrate, bezaﬁbrate) are activators of PPARα,
that are used in the treatment of hyeprlipidemias, and
synthetic PPARβ/δ activators can improve insulin sensitivity
andincreasefattyacidcatabolism.TZDs,syntheticligandsof
PPARγ, such as rosiglitazone and pioglitazone, have already
been introduced into clinical practice for the treatment
of insulin resistance [1, 2]. However, animal studies with
chronic TZD treatment [34, 35] and four large trials of
TZDs with cardiovascular endpoints have also revealed some
unwanted eﬀects of TZDs, such as ﬂuid retention and heart
failure [34]. Today there is therefore increased interest in the
identiﬁcation of selective PPAR modulators (SPPARMs) to
improve metabolic and antiinﬂammatory beneﬁts of PPAR
activation [36].
3. ReninProductionIs Inﬂuencedby
PPARγ Ligands
Cells of the juxtaglomerular apparatus (JGA) express PPARγ
[37]. The JGA produces renin, a 43kDa protease (EC
3.4.99.19, new EC 3.4.23.15) that cleaves angiotensinogen
(AGT) to yield angiotensin I (Ang I). Signals that promote
renin synthesis and secretion can lead to RAAS-dependent
hypertension in humans [25]. Overproduction of renin can
result from enhanced renin gene transcription, as occurs in
spontaneously hypertensive rats, which have mutations in
the transcription factor binding sites of the renin gene [38].
Endogenous and pharmacological PPARγ agonists, such
as unsaturated fatty acids and TZDs, have been shown to
stimulate renin gene expression in renin producing cells,
such as cultured JGA cells [37]( Figure 2). The hunan
renin gene contains two PPARγ binding sequences [37, 39]
and knockdown of PPARγ increases PPRE-driven renin
transcriptioninvitro.JGAspeciﬁcdeletionofPPARγ inmice
results in upregulated renin transcription [40].
Although PPARγ controls renin gene transcription,
potential therapeutical beneﬁts of PPARγ ligand mediated
changes in renin expression have yet to be evaluated.
4. PPARαandPPARγ RegulateAngiotensinogen
GeneExpression
Angiotensionogen (AGT), the ﬁrst substrate of the RAAS, is
an α2-glycoprotein and present at nanomolar concentrations
in serum [25, 41]. Cleavage by renin yields the decapeptide
Ang I, which is then converted by angiotensin converting
enzyme (ACE; EC 3.4.15.1) to the active octapeptide Ang
II (Figure 1). Ang II can induce arteriolar constrictionPPAR Research 3
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Figure 1: Schematic representation of the RAAS cascade. The main signals activating the RAAS are the reduced nephron perfusion due
to lowered arterial mean pressure and the hypovolemia-induced decrease in intratubular sodium/chloride load. Kidney JGA cells produce
renin, which activates the RAAS cascade, yielding two main eﬀector molecules, angiotensin II (AngII) and aldosterone. Other vasoactive
angiotensins can also be produced from Ang-II by the action of diﬀerent aminopeptidases (APs). The main ouputs of RAAS activation are
arteriolar vasoconstriction and ﬂuid retention, which both elevate mean arterial blood pressure. PPARγ is expressed in JGA, the source of
renin and in the distal collecting ducts, targets of aldosterone. Histological image shows a renal glomerule with the longitudnal section of
the aﬀerent arteriole in mouse kidney (hematoxylin-eosin staining, N: 400x).
and consequently elevate systemic vascular tone and blood
pressure [25].
Elevated serum levels of AGT are often recognized as the
cause of hypertension, because higher AGT concentrations
lead to supernormal Ang II production [25]. Under physi-
ological conditions, AGT is mainly synthesized in the liver,
although adipocytes can also liberate physiologically relevant
amounts of AGT [25–27]. In humans, hepatic AGT mRNA
levels correlate positively with plasma AGT concentration
[41, 42]. The human T235 allelic variant of the AGT gene
is associated with enhanced hepatic AGT mRNA synthesis,
higher serum AGT levels, and consequent hypertension [42].
Injection of antisense oligonucleotides against AGT into rats
results in a transient fall in blood pressure accompanied by
decreased levels of plasma AGT and liver AGT mRNA [43].
These data show that AGT production is tightly regulated at
the level of gene expression.
The human AGT promoter is activated by PPARα/RXR
heterodimers and is also bound by hepatocyte nuclear factor
4 (HNF-4), another member of the nuclear receptor family
[24]. The PPARα response region in the AGT promoter
includes a binding site for HNF-4, composed of two
core motifs (RG(G/T)TCA or a closely related sequence)
separated by a single nucleotide (DR1 element). The PPARα
ligand bezaﬁbrate can activate the human AGT promoter
in HeLa cells, which do not express HNF-4, but this4 PPAR Research
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Figure 2: Role of PPARγ in the modulation of the RAAS cascade.
Gene expression of RAAS molecules is modulated by PPARγ.
Although renin production is facilitated by PPARγ activation, the
hypertensive eﬀects of RAAS activation are attenuated by PPARγ
ligands, since these strongly reduce Ang II levels, ACE and AT-R1
gene expression. Telmisartan also exerts AT-R1 blocking properties.
Simultaneously with blockade of AT-R1, the beneﬁcial vasodilator
eﬀects of AT-R2 activation become dominant.
eﬀect is not seen in HNF-4-expressing cell lines, such as
HepG2cellsorHNF-4-transfectedHeLacells,indicatingthat
HNF-4 interferes with promoter binding by PPARα/RXR
heterodimers [24]. These data suggest that AGT promoter
activity can be enhanced by nuclear receptor signaling via
PPARα and RXR, predisposing to hypertension.
In severe obesity, adipose tissue can be an important
source of AGT, potentially contributing to the development
of hypertension and the vascular complications of metabolic
syndrome [26–29]( Figure 3). This idea is supported by
work with a dominant negative P467L mutation in the
ligand-binding domain of PPARγ. In humans the P467L
mutation is associated with severe insulin resistance and
hypertension [44] and homozygous mice with the equivalent
P465L mutation die in utero [44]. Heterozygous mice are
hypertensive and show increased gene expression of AGT in
subcutaneous adipose tissue. Increased AGT production by
white adipose tissue in this mouse model not only induces
hypertension; it also increases lipogenic gene expression,
leading to abnormal fat distribution [44]. The PPARγ ligand
rosiglitazone, however, has no eﬀect on AGT expression in
human adipocytes, and an action of PPARγ on adipocyte
AGT gene regulation in humans has not been demonstrated
[45].
5. PPARγ andPPARα Modulate Expressionof
AngiotensinConvertingEnzyme
Inhibition of ACE results in decreased production of Ang
II and decreased metabolism of bradykinin, leading to
systemic dilation of blood vessels and a decrease in arterial
blood pressure [46]. Moreover, Ang II-induced aldosterone
secretion is also reduced, leading to decreased water and
sodium reabsorption and a reduction in extracellular ﬂuid
volume [25, 46].
Ligands of PPARα and PPARγ can suppress the gene
expression of ACE in vascular tissues [13, 47, 48]( Figure 2).
In streptozotocin-induced diabetes in rats, the PPARα
agonist bezaﬁbrate and the PPARγ ligand pioglitazone can
equally protect against the streptozotocin-induced upreg-
ulation of ACE in the aortic wall. This action of PPARs
promotes beneﬁcial antiatherogenic eﬀects under insulin
resistant conditions [13]. Similarly, ACE gene expression
in obese Zucker rats is reduced by chronic treatment with
rosiglitazone [47]; and clinical studies have demonstrated
that the partial PPARγ agonist telmisartan inhibits ACE and
blocks Ang II receptor type 1 (AT-R1) [36, 49]. This com-
bined ACE suppressing and Ang II receptor blocking (ARB)
eﬀectstrengthensthevascularprotectionconferredtohyper-
tensive type 2 diabetic patients by the antiinﬂammatory and
antiatherogenic consequences of PPARγ activation [36, 46]
(Figure 2).
In contrast, antihypertensive eﬀect of ﬁbrates is con-
troversial, since although these compounds reduce blood
pressure in patients with hypertriglyceridemia [22], they
have the opposite eﬀect in glucocorticoid-induced diabetes
[50]. The existence of antihypertensive and antiatherogenic
actions of PPARα are also challenged by work with the
Tsukuba hypertensive mouse (THM), a model of Ang II-
induced hypertension [19]. In the THM system, transgenic
expression of the entire human RAAS leads to high Ang II
and aldosterone levels, causing hypertension and atheroscle-
rosis. In PPARα-deﬁcient THM animals this hypertension
is totally abolished [19], and this is accompanied by a
reduction in plasma renin and by a normalization of serum
aldosterone. PPARα-deﬁcient THM animals also fail to
develop aortic sclerosis in response to an atherogenic diet,
andthespontaneousformationoffoamcellsfromperitoneal
macrophages is also markedly reduced in these animals. This
suggests that the lack of PPARα protects against the oxidative
stress normally seen in THM mice, possibly by reducing Ang
II levels [19]. Thus these data, while conﬁrming that PPARα
regulates the RAAS, indicate that PPARα activation in this
model aggravates hypertension and fails to protect against
atherogenesis.
6. Angiotensin-IIReceptor Blockade and
Actions of PPAR/RXR Heterodimers
Angiotensin receptor blockers (ARBs) are used to treat
hypertension [25, 46]. The protective eﬀects of ARBs are
based on blockade of AT-R1s. In addition to blocking
signaling downstream of AT-R1s, this blockade diverts Ang
II to Ang II type 2 receptors (AT-R2s), resulting in release
of the vasodilator nitric oxide (NO) [46]( Figure 2). In
clinical practice, blockade of AT-R1s is often combined
with ACE-inhibition, and this treatment strategy (known asPPAR Research 5
ATG
Renin
Ang-I Ang-II (b)
(c)
(a)
(d)
ACE
PPARγ∗
AT-R1 PPARγ∗
PPARγ TGFβ production
Oxidative stress
p27, ﬁbronectin
Mesangial cell
TGFβ-R
Mesangial cell hypertrophy
glomerulosclerosis
Proinﬂammatory mediators
Vascular inﬂammation PPARγ
Cell proliferation
ECM production
VCAM expression
ROS generation
VSMC
AT-R1 PPARγ∗ AT-R1 PPARγ∗
Ang-II Ang-I
ACE
PPARγ∗
Ischemic heart disease
Heart hypertrophy
PPARγ ATG production
PPARγ
Lipoxidation
end products Insulin
resistance
Adipocyte
Proinﬂammatory
cytokines
βMHC upregulation
αMHC downregulation
ANF expression
Cardiomyocyte
Chronic
hypertension
Ang-I Ang-II
ACE
PPARγ∗
Pathway without PPARγ activation
Arrest point due to PPARγ activation
Figure 3: Paracrine eﬀects of the RAAS and their modulation by PPARγ. In adipocytes (a) PPARγ activation is suggested to reduce ATG
synthesis, impeding RAAS activation; this can ameliorate hypertension in obese diabetic patients. Independently of RAAS modulation,
PPARγ improves insulin action in adipocytes, reducing the production of proinﬂammatory cytokines and reducing the risk of atherogenesis
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through both direct AT-R1 inhibition and downregulation of ACE/AT-R1 gene expression. TGFβ: transforming growth factor-β,E C M :
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doubleRAASblockade)caneﬀectivelyreducebloodpressure
in high-risk patients [46]. The advantage of ACE inhibitors
is their ability to reduce circulating and tissue Ang II levels,
while ARBs potentiate the beneﬁcial blood pressure lowering
eﬀects of bradykinin, including AT-R2 mediated generation
of NO (Figure 2).
Two ARBs, telmisartan and irbesartan, act as selective
PPAR modulators (SPPARMs) [36, 49, 51, 52]. Selective
PPARγ modulation is a new and promising pharmacological
approach, based on selective receptor-cofactor interactions
and target gene regulation without unwanted PPARγ side
eﬀects, such as the well-known water and sodium reten-
tion associated with TZD treatment [36, 53]. Due to
its partial PPARγ agonist eﬀect, telmisartan inhibits vas-
cular ACE activity [13], AT-R1 expression [54, 55]a n d
increasesendothelialNOsynthesis[56],preventingoxidative
stress and endothelial dysfunction more eﬀectively than
non PPARγ- a g o n i s tA R B s[ 13]. Longterm treatment (4–24
weeks) with telmisartan, in monotherapy or in combination
with other antihypertensive drugs reduces systolic blood
pressure by 4–4.6mmHg and diastolic blood pressure by 3–
3.6mmHg [57]. This compares favorably with the reduction
of systolic blood pressure by 3mmHg by pioglitazone in
the Prospective Pioglitazone Clinical Trial in Macrovascular
Events (PROactive) study [21, 58]. This degree of improve-
ment provides sustained blood pressure control of mild to6 PPAR Research
moderate hypertension [59]. In particular, the PROactive
study indicates a clear clinical beneﬁt of pioglitazone in the
risk reduction of cardiovascular events in patients with type
2 diabetes, since addition of pioglitazone to conventional
antihypertensive therapy reduced macrovascular outcomes
by 10%, nonfatal myocardial infarction and stroke by 16%
compared with placebo [60]. Pioglitazone might combine
antidiabetic, antiinﬂammatory and antiatherogenic beneﬁts
withantihypertensive action of PPARγ activation[60].How-
ever, the recent Rosiglitazone Evaluated for Cardiac Out-
comes and Regulation of glycaemia in Diabetes (RECORD)
trial conﬁrmed the increased risk of heart failure events in
people treated with rosiglitazone, which limits the future
use of TZDs in hypertensive patients [61]. Telmisartan
was expected to provide a new therapeutic option for
improved cardiovascular risk management in metabolic
diseases since additionally to its ARB activity, it binds to
PPARγ [55]. However, neither the Ongoing Telmisartan
Alone and Combination with Ramipril Global End Point
Trial (ONTARGET) nor the Telmisartan Randomized Ass-
esment Study in ACE-1 Intolerant Subjects (TRANSCEND)
showed any signiﬁcant advantage of telmisartan in reducing
cardiovascular endpoints in high-risk patients [62].
PPARγ also blocks the action of Ang II by transcription-
ally repressing AT-R1 gene expression in VSMCs [16, 36,
49, 51, 54]( Figure 2). In addition to its role as a regulator
of vascular tone, AT-R1 activation contributes to vascular
lesions and atherogenesis by promoting VSMC proliferation
[32, 63]; therefore a suppressed Ang II response can poten-
tially slow the progression of atherosclerosis. VSMCs express
the retinoid receptors RARα and RXRα. In the arterial wall,
long-term exposure to all-trans retinoic acid or RARα/RXRα
agonists dose-dependently inhibits Ang II-induced VSMC
proliferation and the expression of c-fos and transforming
growth factor-β (TGFβ) mRNA, providing antiprolifera-
tive/antiinﬂammatory beneﬁts and vascular protection in
hypertensive patients [16, 63]. The likely mechanism of the
reduced Ang II response upon retinoid receptor activation is
RAR/RXR mediated downregulation of AT-R1 expression in
VSMCs, similar to the action of PPARγ ligands [16]. Ang-
II-mediated vascular damage and endothelial dysfunction in
rats are also reduced by the activation of PPARα, but this
eﬀect is due to the elevated endothelial NO synthesis and
reduced oxidative stress and not to AT-R1 blockade [64].
7. PPARγ LigandsReduce Aldosterone Levels:
Vasoprotection andCardioprotection
The main eﬀect of aldosterone is to facilitate epithelial
sodium and water resorbtion, leading to the expansion of
total body ﬂuid volume and secondarily contributing to
the elevation of systemic blood pressure [25]. Permanently
highaldosteroneproductioncausesmicrovascularinjuryand
cardiac hypertrophy, major contributors to hypertension-
associated cardiovascular morbidity and mortality [46].
Ang II is the main trigger of aldosterone secretion in
the adrenal cortex, and AT-R1 blockers therefore reduce
plasma aldosterone levels [65]. Recent studies indicate that
the PPARγ agonist telmisartan, which is an ARB and reduces
vascular ACE activity through PPARγ,i sm o r ee ﬀective at
reducing aldosterone levels than non-PPARγ ligand ARBs
[36, 51, 65]. PPARγ ligands such as rosiglitazone and PD168
cause a signiﬁcant drop in blood pressure in hyperten-
sive rats, and increase urinary aldosterone excretion [18].
The reduced heart-to-body weight ratio of ligand-treated
animals indicates that PPARγ activation can also diminish
aldosterone-induced heart hypertrophy [18]. These results
support the idea that AT-R1 blockade in combination with
PPARγ stimulation has a more potent aldestrerone-lowering
eﬀect than ACE-inhibition alone, and is a promising strategy
for preventing the increased body ﬂuid volume and cardiac
and vascular damage induced by enhanced RAAS activity
(Figure 3).
8. Volume Overload is the Adverse Effect of
PPARγ Activation
Although PPARγ stimulation reduces aldosterone lev-
els, thereby countering water and sodium reabsorption,
PPARγligands such as rosiglitazone and PD168, concomi-
tantly with their antihypertensive eﬀects, cause a signiﬁcant
elevation of total body ﬂuid volume in hypertensive rats
[18]. Similarly, edema and water retention are frequently
occurring side eﬀects in many patients treated with TZDs
[3, 34, 35, 66, 67]. This eﬀect can normally be treated with
diuretics; however, this cannot fully restore the interstitial
ﬂuid volume in TZD-treated diabetic or atherosclerotic
patients if glomerulosclerosis or diabetic glomerulonephritis
with osmotic diuresis has developed. Adverse metabolic
eﬀects of loop diuretics also contraindicate their administra-
tion in many cases [35, 67].
Fluid retention caused by TZDs might be a consequence
of the activation of PPARγ expressed in the kidney collecting
ducts, since kidney epithelial PPARγ positively regulates
sodium and water resorbtion [68]. Other factors besides the
enhanced sodium resorbtion might also be involved in the
edematous side eﬀects of PPARγ ligands, since individuals
with single nucleotide polymorphisms in the β1 adrenergic
receptor gene develop peripheral edema more frequently
during PPARγ agonist treatment [69]. In contrast, polymor-
phisms in the PPARγ regulated renin and endothelin-1 genes
are associated with a reduced risk of water retention and
edema [69].
Fluid retention upon PPARγ ligand administration does
not seem to interfere with the beneﬁcial blood pressure
lowering eﬀects of these drugs [18]; however, four large trials
of TZDs with cardiovascular endpoints have underlined
the harmful side eﬀects of PPARγ activation in diabetic
patients with hypertension or accompanying heart problems
[34]. Although PPARγ agonists reduce cardiovascular risk
factors [3, 21], congestive heart failure or other ischemic
heart diseases can develop unexpectedly in patients treated
with TZDs [34]. Edema and ﬂuid retention provide a
possible explanation for this, since expansion of extracel-
lular ﬂuid volume diminishes cardiac output, triggering a
compensatory cardiac hypertrophy, eventually resulting inPPAR Research 7
congestive heart failure [34]. To avoid unwanted cardiac side
eﬀects, administration of TZDs is being restricted, and much
attention is being directed to the development of SPPARMs
in order to improve the safety of PPARγ modulation [57].
9. RAAS Dependent Renal InjuryIs
a Risk Factor for Hypertension:
Renoprotective PPARγ
Dysfunction of the RAAS can develop into kidney dis-
ease, which can both contribute to and be exacerbated
by high blood pressure and cardiovascular morbidity [70,
71]( Figure 3). The importance of RAAS blockade in the
treatment of nephropathy has been clearly established,
although the renal beneﬁts of ARBs and ACE inhibitors
seem to be independent of their blood pressure lowering
eﬀects [71]. Several lines of evidence indicate that the local
actions of the RAAS are not only involved in the regulation
of renal hemodynamics, but also play a central role in kidney
inﬂammation and the progression of microvascular lesions
[70–76]. Recent reports indicate that Ang II has proinﬂam-
matory, mitogenic and proapoptotic eﬀects; and therefore
intrarenal Ang II production is an important factor in the
initiation of glomerular and tubulointerstitial inﬂammation,
contributing to the development of nephropathy, vascular
injury and hypertension [73–78].
Spontaneously hypertensive rats or rats with strep-
tozotocin-induced diabetes develop signiﬁcant glomeru-
lar damage, characterized by sclerosis, hypercellularity,
podocyte injury with abnormal urinary protein excretion,
andtubulointerstitialinﬂammationcharacterizedbyﬁbrosis,
type IV collagen staining and expression of TGFβ [47, 71,
74]. Other hallmarks of kidney disease are enhanced activity
of Ang II, with increased AT-R1 expression and down-
regulated expression of PPARγ [71]. All these indicators of
glomerular and tubulointerstitial damage can be improved
by administration of ARBs [48, 71].
Reduction of blood pressure without RAAS blockade is,
however, less eﬀective in the mitigation of renal disease.
Thus underlines the fact that kidney injury is primarily due
to the inﬂammatory, proliferative and thrombotic eﬀects of
Ang II, which adversely aﬀect renal perfusion and increase
oxidative stress [33, 71, 75–79]. Clinical evidence suggests
that telmisartan, the PPARγ ligand ARB, is more potent than
other ARBs or ACE inhibitors at slowing the development of
nephropathy [49, 51, 76]. Telmisartan also attenuates renal
damage in salt-induced hypertensive rats, possibly due to
the improved endothelial NO synthase coupling and renal
autoregulation [80]. Other PPARγ ligands, such as TZDs,
also decrease inﬂammatory hallmarks in the kidney, such as
glomerularcellproliferation,apoptosis,andpodocyteinjury;
moreover, these ligands can also reduce the inﬂammatory
response to Ang II in kidney mesangial cells [13, 23, 48,
75]. The Diabetes REduction Assesment with ramipril and
rosiglitazoneMedication(DREAM)trialreportedthatRAAS
blockade with the ACE inhibitor ramipril can not alter renal
outcome in patients with impaired glucose tolerance and/or
impaired fasting glucose levels [81], while the same study
conﬁrmed that the TZD-type PPARγ ligand rosiglitazone
reduces diabetic kidney complications. The mechanism of
renoprotection by PPARγ agonists is multifactorial, and
besides antiinﬂammatory actions includes antiﬁbrotic eﬀects
and suppression of the RAAS [23]. Rosiglitazone appears
to reduce AT-R1 expression in the kidney, in addition to
its repression of Ang II synthesis, while the ARB action of
telmisartan makes this compound a promising agent that
combines the classical antiinﬂammatory PPARγ functions
with a potent blood pressure lowering eﬀect [47, 70–78, 82].
Due to its lipophilic character and long half-life, telmisartan
isconsideredtohavetherapeuticpotentialnotonlyinRAAS-
dependenthypertension,butalsointhetreatmentofdiabetic
kidney injury [70, 77, 79]. In contrast with PPARγ, the
possible role of PPARα in the modulation of local RAAS
activation in the kidney remains undeﬁned. A recent study
documented that increased PPARα expression can also play
a protective role in hypertensive renal injury in rats with
hypertension induced by NO withdrawal and high salt diet
[83]. However, although plasma RAAS activity is reduced
in rats with high-salt diet induced hypertension, local
RAAS activation in the kidney leads to severe renal damage
[77–80].
10. Involvement of PPARγ in
the Effects of RAAS Blockade on
LipidandCarbohydrateMetabolism
Inhibition of the RAAS delays or prevents the development
of diabetes [52, 84]. The mechanisms underlying this
protective eﬀect appear to be complex and might involve
the adipose tissue RAAS, which plays an important role
in the metabolism of this tissue, including regulation of
the production of pro-inﬂammatory and antiinﬂammatory
adipocytokines [82, 85, 86]( Figure 3).
The regulation of PPARγ expression by aldosterone
and Ang-II might inﬂuence insulin sensitivity [57, 85].
In rats, chronic treatment with AT-R1 antagonist leads
to hypotrophy of epididymal and retroperitoneal adipose
tissue, and this is followed by reduced serum levels of leptin
and increased levels of adiponectin [87]. Furthermore, AT-
R1 blockade increases epididymal expression of AT-R2, fatty
acid synthase and PPARγ, and decreases the expression of
tumor necrosis factor alpha (TNFα). Adipokine synthesis
and reduced TNFα production within adipose tissue are
therefore beneﬁcial consequences of local AT-R1 inhibition,
AT-R2 stimulation, and perhaps PPARγ activation [87].
A recent study assessed the binding aﬃnity of the ARBs
telmisartan, valsartan and lisinopril to PPARγ, ﬁnding that
telmisartan is the most potent PPARγ agonist [88]. In the
same study, all tested ARBs increased the phosphoryla-
tion of insulin-like growth factor receptor-1 and AKT in
skeletal muscle cells, and also increased the secretion of
the adipokine visfatin by adipocytes [88]. In hypertensive
diabetic rats telmisartan improves the metabolic proﬁle
and reduces blood pressure to normotensive values faster
than the ARB valsartan or the TZD pioglitazone [89].
In addition, telmisartan increases macrophage cholesterol
eﬄux by enhancing expression of the ATP binding cassette8 PPAR Research
transportersA1andG1(ABCA1/G1)andofscavengerrecep-
tor class B type I, and these eﬀects are dependent on PPARγ
regulated pathways [90]. The obesity-associated decrease in
adiponectin and the increase in proinﬂammatory adipokines
are linked to the development of insulin resistance, which is
coupled to altered macrophage lipid metabolism, enhanced
atherogenesis; and hypertension [1, 2]. The consequences
of PPARγ activation on insulin signaling, adiponectin and
adipokine geneexpression, aswellasmacrophagecholesterol
handling, might underlie the mechanism of the additional
antidiabetic and vasoporotective eﬀects of AT-R1 blockade.
The metabolic beneﬁts of RAAS blockade have been
challenged by the DREAM trial. This study shows that
the ACE inhibitor ramipril does not reduce new-onset
diabetes, although it does signiﬁcantly increase the regres-
sion to normogylcemia, suggesting beneﬁcial eﬀects on
glucose homeostasis [91]. The DREAM trial involved a
relatively young patient population with moderate hyper-
tension and without cardiovascular disease, which might
explain the lack of an eﬀect on new-onset diabetes [81,
91]. The question of whether the prevention of new-onset
diabetes leads to a reduction in cardiovascular disease
events might be resolved by the results of two ongo-
ing clinical trials, Nateglinide And Valsartan in Impaired
Glucose Tolerance Outcomes Research (NAVIGATOR) and
ACE Inhibitor-based versus Diuretic-based Antihypertensive
Primary Treatment in Patients with PreDiabetes (ADaPT)
[62].
11. Conclusion and Outlook
Gene expression of RAAS molecules is modulated by PPARγ,
and to a lesser extent by PPARα, making the ligands of these
transcription factors potential blood pressure modulating
drugs in RAAS-dependent hypertension [3, 21, 70]. The
bloodpressurereductionachievedbyPPARγ ligandssuggests
that PPARγ activation can be used in the long-term control
of moderate hypertension [92]. Nephropathy, a predisposing
risk factor for hypertension, can be also ameliorated by
PPARγ and PPARα, athough these renoprotective eﬀects are
due to antiinﬂammatory and vasoprotective PPARγ/PPARα
properties and the reduction in the proinﬂammatory Ang
II eﬀects, and are independent of the systemic RAAS
modulation. Transcription of angiotensinogen seems also to
be regulated by PPARα, although the value of PPARα as a
therapeutic target in RAAS dependent hypertension should
be evaluated.
Since activation of PPARγ modulates both the systemic
and paracrine eﬀects of the RAAS, selective PPARγ modula-
tors may provide blood pressure lowering beneﬁts with syn-
ergistic vasoprotective, renoprotective and cardioprotective
consequences. However, TZD-type PPARγ ligands disturb
waterand salthomeostasisin susceptible individuals, leading
to adverse cardiac side eﬀects, which is today a strong
limitation for the use and future impact of the currently
available PPARγ activators. The development of SPPARMs
and further studies in mice with tissue speciﬁc deletion
of PPAR isoforms will facilitate better understanding and
pharmacological modulation of nuclear receptor functions
in hypertension.
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